The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Human urinary kallikrein for cerebral infarction
Author(s): 
Pages: 268-269
Year: Issue:  2
Journal: The Journal of Practical Medicine

Keyword:  脑梗塞激肽释放酶类;
Abstract: 目的:探讨人尿激肽原酶治疗脑梗死的临床疗效.方法:脑梗死患者120例,病程3 h~12 d.给予生理盐水100 mL+人尿激肽原酶0.15 PNAU静脉滴注.每日1次,连用7~14 d.于治疗前后进行神经功能缺损程度评分(NIHSS),并记录不良反应.结果:人尿激肽原酶治疗脑梗死总有效率达61.7%(74/120).120例脑梗死患者治疗前NIHSS评分为9.9±3.9,治疗7~14 d后,N1HSS评分为5.5±2.8,治疗前后NIHSS评分差异有显著性(P<0.05).<48 h与48 h~12 d开始治疗的病例临床疗效差异无显著性.颈内动脉系统与椎基底动脉系统的脑梗死的治疗效果差异无显著性.结论:人尿激肽原酶治疗脑梗死有效且安全,在脑损害晚期仍具有促进修复和再生能力而产生神经保护作用.激肽原酶治疗脑梗死具有重要的价值.
Related Articles
No related articles found